tbuckley/cabot-search huggingface dataset:
The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years
Authors: Chiara Lobetti-Bodoni, Paola MV Rancoita, Silvia Montoto, Armando Lopez-Guillermo, Annarita Conconi, Rita Coutinho, Janet Matthews, Silvia Franceschetti, Francesco Bertoni, Franco Cavalli, Michele Ghielmini, Andrew Lister, Emili Montserrat, Emanuele Zucca
Journal: Blood (2011)
NADPH oxidase in brain injury and neurodegenerative disorders
Authors: Merry W. Ma, Jing Wang, Quanguang Zhang, Ruimin Wang, Krishnan M. Dhandapani, Ratna K. Vadlamudi, Darrell W. Brann
Journal: Molecular Neurodegeneration (2017)

Oxidative stress is a common denominator in the pathology of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, as well as in ischemic and traumatic brain injury. The brain is highly vulnerable to oxidative damage due to its high metabolic demand. However, therapies attempting to scavenge free radicals have shown little success. By shifting the focus to inhibit the generation of damaging free radicals, recent studies have identified NADPH oxidase as a major contributor to disease pathology. NADPH oxidase has the primary function to generate free radicals. In particular, there is growing evidence that the isoforms NOX1, NOX2, and NOX4 can be upregulated by a variety of neurodegenerative factors. The majority of recent studies have shown that genetic and pharmacological inhibition of NADPH oxidase enzymes are neuroprotective and able to reduce detrimental aspects of pathology following ischemic and traumatic brain injury, as well as in chronic neurodegenerative disorders. This review aims to summarize evidence supporting the role of NADPH oxidase in the pathology of these neurological disorders, explores pharmacological strategies of targeting this major oxidative stress pathway, and outlines obstacles that need to be overcome for successful translation of these therapies to the clinic.
Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method
Authors: Valentín García-Gutierrez, Maria Teresa Gómez Casares, Jimenez Velasco Antonio, Alonso Juan Manuel, Santiago Osorio, Juan Carlos Hernández-Boluda, Jose Manuel Puerta, Rosa Collado, Maria Jose Ramirez, Fatima IbaÃ±ez, María Luisa Martín Mateos, Juan Diego Rodriguez Gambarte, Carolina Martinez Laperche, Sara Redondo, Montse Gomez, DV Suarez Fiallo, Alicia Rodriguez Fernandez, Concepcion Ruiz, Juan Luis Steegmann
Journal: Blood (2015)
Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial
Authors: Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, Sebastian Grosicki
Journal: Blood (2015)
Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study
Authors: Susan R Kahn, Andrew Hirsch, Margaret Beddaoui, Arash Akaberi, David Anderson, Philip S Wells, Marc Rodger, Susan Solymoss, Michael J. Kovacs, Lawrence Rudski, Avi Shimony, Carole Dennie, Chris Rush, William H. Geerts, Paul Hernandez, Shawn Aaron, John T Granton
Journal: Blood (2015)
Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study
Authors: Delva Deauna-Limayo, Omar Aljitawi, Siddhartha Ganguly, Sunil Abhyankar, Jo Wick, Joseph McGuirk
Journal: Blood (2010)
Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis
Authors: Cristina Beltrami, Marie Besnier, Saran Shantikumar, Andrew I.U. Shearn, Cha Rajakaruna, Abas Laftah, Fausto Sessa, Gaia Spinetti, Enrico Petretto, Gianni D. Angelini, Costanza Emanueli
Journal: Molecular Therapy (2017)
Introduction of Constitutivelly Active Akt in Primary CLL B-Cells Results in Upregulation of Mcl-1, Bcl-XL and Cyclin D3 and Promotes Leukemic Cell Survival.
Authors: Pablo Longo, Stefania Gobessi, Luca Laurenti, Simona Sica, Giuseppe Leone, Dimitar G. Efremov
Journal: Blood (2006)
Prognostic Significance of Quality of Life in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Betty K. Hamilton, Lisa Rybicki, Donna M Abounader, Jane Dabney, Robert M Dean, Hien K. Duong, Brian T. Hill, Aaron Gerds, Deepa Jagadeesh, Matt E. Kalaycio, Christine Lawrence, Linda McLellan, Brad Pohlman, Ronald M. Sobecks, Brian J. Bolwell, Navneet S. Majhail
Journal: Blood (2014)
Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14
Authors: James J. Hsieh, Mahtab Marker, David Chen
Journal: European Urology (2017)
Functional SDF-1 Secretion from BM Stromal Cells Is a Cell Contact-Dependent Event Mediated by Cx43 and Cx45 Gap-Junctions
Authors: Amir Schajnovitz, Tomer Itkin, Aya Ludin, Alexander Kalinkovich, Kfir Lapid, Rony Seger, Tsvee Lapidot
Journal: Blood (2008)
Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma.
Authors: Isabelle Vande Broek, Xavier Leleu, Dan Duda, Benjamin Van Camp, Karin Vanderkerken, Ivan van Riet
Journal: Blood (2009)
Analysis on the Correlation of RPS19 Expression Level to Diamond-Blackfan Anemia; Insights from the Expression Level of RPS19 Point Mutants in Erythroid Cell Lines.
Authors: Madoka Kuramitsu, Isao Hamaguchi, Mizukami Takuo, Atsuko Masumi, Haruka Momose, Kazuya Takizawa, Masayo Motizuki, Seishirou Naito, Kazunari Yamaguchi
Journal: Blood (2006)
Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas
Authors: Roopesh R. Kansara, Joseph M. Connors, Kerry J. Savage, David W Scott, Randy D. Gascoyne, Alina S Gerrie, Laurie H. Sehn, Diego Villa
Journal: Blood (2015)
Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).
Authors: Magdalena Plasilova, Hans B. Ommen, Jaroslav Jelinek, Jean-Pierre Issa, Elyn R. Riedel, Susan Mathew, Amy Chadburn, Pengbo Zhou, Peter Hokland, Malcolm A.S. Moore
Journal: Blood (2006)
Using Platelet Proteomics as a Marker of Cardiac Failure in a Pacing-Induced Pig Heart Failure Model
Authors: Stephen W. Rothwell, Mark C. Haigney, Shao-kui Wi, Madelaine Clark, Ofer Eidelman, Catherine Jozwik, Meera Srivastava, Gregory P. Mueller, Matie Shou, Harvey B. Pollard
Journal: Blood (2008)
High Dose Chemotherapy with Autologous Stem Cell Transplantation in Malignant Lymphoma - A Single Center Experience.
Authors: Ulrich J.M. Mey, Vandana Jha, Marcus Gorschlueter, John W. Strehl, Tilman Sauerbruch, Axel G. Glasmacher, Ingo G.H. Schmidt-Wolf
Journal: Blood (2005)
Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers.
Authors: Wojciech Jurczak, Michal Szymczyk, Agnieszka Giza, Monika Joks, Elzbieta Kisiel, Beata Stella-Holowiecka, Piotr Boguradzki, Tomasz Wrobel, Magdalena Sikorska, Wanda Knopinska-Posluszny, Ewa Kalinka-Warzocha, Jan Walewski, Aleksander B. Skotnicki
Journal: Blood (2009)
Killing of Quiescent and Cycling Chronic Myeloid Leukemia CD34+ Cells by Autologous Ex-Vivo Expanded Natural Killer Cells Is Enhanced by Bortezomib Treatment.
Authors: Agnes S.M. Yong, Nicole Stephens, Keyvan Keyvanfar, Bipin N. Savani, Rhoda Eniafe, Maria Berg, Elaine M. Sloand, Richard Childs, A. John Barrett
Journal: Blood (2010)
Effects of loading concentration, blood and synovial fluid on antibiotic release and anti-biofilm activity of bone cement beads
Authors: Devendra H. Dusane, Scott M. Diamond, Cory S. Knecht, Nicholas R. Farrar, Casey W. Peters, Robert P. Howlin, Matthew C. Swearingen, Jason H. Calhoun, Roger D. Plaut, Tanya M. Nocera, Jeffrey F. Granger, Paul Stoodley
Journal: Journal of Controlled Release (2017)

Antibiotic loaded cement beads are commonly used for the treatment of biofilm related orthopaedic periprosthetic infections; however the effects of antibiotic loading and exposure of beads to body fluids on release kinetics are unclear. The purpose of this study was to determine the effects of (i) antibiotic loading density (ii) loading amount (iii) material type and (iv) exposure to body fluids (blood or synovial fluid) on release kinetics and efficacy of antibiotics against planktonic and lawn biofilm bacteria. Short-term release into an agar gel was evaluated using a fluorescent tracer (fluorescein) incorporated in the carrier materials calcium sulfate (CaSO4) and poly methyl methacrylate (PMMA). Different fluorescein concentrations in CaSO4 beads were evaluated. Mechanical properties of fluorescein-incorporated beads were analyzed. Efficacy of the antibiotics vancomycin (VAN) or tobramycin (TOB) alone and in combination was evaluated against lawn biofilms of bioluminescent strains of Staphylococcus aureus and Pseudomonas aeruginosa. Zones of inhibition of cultures (ZOI) were measured visually and using an in-vivo imaging system (IVIS). The influence of body fluids on release was assessed using CaSO4 beads that contained fluorescein or antibiotics and were pre-coated with human blood or synovial fluid. The spread from the beads followed a square root of time relationship in all cases. The loading concentration had no influence on short-term fluorescein release and pre-coating of beads with body fluids did not affect short-term release or antibacterial activity. Compared to PMMA, CaSO4 had a more rapid short term rate of elution and activity against planktonic and lawn biofilms. This study highlights the importance of considering antibiotic loading and packing density when investigating the clinical application of bone cements for infection management.
Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience
Authors: Ekaterina Bulycheva, Jiri Mayer, William Hermann Krüger, Peter Dreger, Anna Mies, Zuzana Sustkova, Zdenek Racil, Jirina Prochazkova, Eva Walter, Carsten Hirt, Mark Ringhoffer, Wolfgang E Berdel, Hubert Serve, Christoph Rollig, Katja Sockel, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede, Uwe Platzbecker
Journal: Blood (2015)
Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma
Authors: T. Oliver, K.-P. Dieckmann, H. Steiner, I. Skoneczna
Journal: Journal of Clinical Oncology (2005)

4572 Introduction: In the last 10 years there has been reports of increased risk of late occurrence of non-germ cell cancers 20 years or more after radiation as adjuvant for stage 1 seminoma. Prompted by a randomised study suggesting that 1 course carboplatin was equally effective but also in the short term(5years) was associated with significantly less tumours in the contrateral testis, this abstract reports 10 and 20 year follow up experience from the phase 2 studies of 1 and 2 course carboplatin that preceeded the randomised trial. Methods: Research of published papers identified 5 publications and 2 abstract with 837 cases followed for a median of 75 months. The data for relapse, germ cell cancer mortality, 2nd GCT and non-GCT causes of death have been pooled and the authors contacted for follow up. Results: 521 patients received 2 courses with 15(2.9%) relapse, 0 GCT deaths 0 second GCT and 7(1.3%) non GCT deaths (p ns). 316 received 1 course with 14(4.4%) relapses, 10/16(8.6%) in those receiving 400mg/m2 and 5/2004(2.5%) in those receiving AUCx7 (p<03). There were 3(1%) 2nd GCT all after 7 years, no GCT or non GCT deaths. Conclusion: These results are as good as any that have been reported for radiotherapy and give added confidence in the safety of carboplatin. The data suggests a sharp dose response relationship and suggest future studies should address this issue further No significant financial relationships to disclose.
Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.
Authors: Patrizia Zappasodi, Alessandro Corso, Chiara Rusconi, Mara De Amici, Erica Consensi, Cristiana Pascutto, Marzia Varettoni, Silvia Mangiacavalli, Gianmatteo Pica, Mario Lazzarino
Journal: Blood (2005)
Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling
Authors: Daniel C. Berwick, Behzad Javaheri, Andrea Wetzel, Mark Hopkinson, Jonathon Nixon-Abell, Simone Grannò, Andrew A. Pitsillides, Kirsten Harvey
Journal: Molecular Neurodegeneration (2017)

LRRK2 mutations and risk variants increase susceptibility to inherited and idiopathic Parkinson's disease, while recent studies have identified potential protective variants. This, and the fact that LRRK2 mutation carriers develop symptoms and brain pathology almost indistinguishable from idiopathic Parkinson's disease, has led to enormous interest in this protein. LRRK2 has been implicated in a range of cellular events, but key among them is canonical Wnt signalling, which results in increased levels of transcriptionally active β-catenin. This pathway is critical for the development and survival of the midbrain dopaminergic neurones typically lost in Parkinson's disease. Here we use Lrrk2 knockout mice and fibroblasts to investigate the effect of loss of Lrrk2 on canonical Wnt signalling in vitro and in vivo. Micro-computed tomography was used to study predicted tibial strength, while pulldown assays were employed to measure brain β-catenin levels. A combination of luciferase assays, immunofluorescence and co-immunoprecipitation were performed to measure canonical Wnt activity and investigate the relationship between LRRK2 and β-catenin. TOPflash assays are also used to study the effects of LRRK2 kinase inhibition and pathogenic and protective LRRK2 mutations on Wnt signalling. Data were tested by Analysis of Variance. Loss of Lrrk2 causes a dose-dependent increase in the levels of transcriptionally active β-catenin in the brain, and alters tibial bone architecture, decreasing the predicted risk of fracture. Lrrk2 knockout cells display increased TOPflash and Axin2 promoter activities, both basally and following Wnt activation. Consistently, over-expressed LRRK2 was found to bind β-catenin and repress TOPflash activation. Some pathogenic LRRK2 mutations and risk variants further suppressed TOPflash, whereas the protective R1398H variant increased Wnt signalling activity. LRRK2 kinase inhibitors affected canonical Wnt signalling differently due to off-targeting; however, specific LRRK2 inhibition reduced canonical Wnt signalling similarly to pathogenic mutations. Loss of LRRK2 causes increased canonical Wnt activity in vitro and in vivo. In agreement, over-expressed LRRK2 binds and represses β-catenin, suggesting LRRK2 may act as part of the β-catenin destruction complex. Since some pathogenic LRRK2 mutations enhance this effect while the protective R1398H variant relieves it, our data strengthen the notion that decreased canonical Wnt activity is central to Parkinson's disease pathogenesis.
Minimal Residual Disease Status at Day +100 Post Allogeneic Hematopoietic Stem Cell Transplantation Is a Powerful Predictor for Post-Transplant Outcome In Patients with High Risk Acute Leukemia
Authors: XiaoWen Tang, Xingwei Sun, Shengli Xue, Xiaolan Shi, Mingqing Zhu, Wenhong Shen, Li Chen, Aining Sun, Wu Depei
Journal: Blood (2010)
A Human Antibody, Cloned from a Patient with Heparin-Induced Thrombocytopenia, That Binds Heparin/Platelet Factor 4 Complexes.
Authors: Scott K. Dessain, Katherine E. Rybinski, Sharad P. Adekar, Lubica Rauova, Bruce S. Sachais, Steven E. McKenzie, Michael P. Reilly
Journal: Blood (2005)
Warning to GMC
Authors: R. M Goss, J. Hardy
Journal: BMJ (2001)

Editor—How interesting that Heath overlooks the General Medical Council's primary responsibility—protecting patients.1 Everything else flows from this duty. To relate empowering patients to political abuse and coercion seems disingenuous. Why elevate to top priority protecting doctors' freedom to conduct their practice however they see fit? It suggests a desire to thwart the government's goal of putting patients, their views, and their interests at the heart of the NHS.

Most doctors also come from a relatively narrow, affluent, and well educated section of society. Lay people contributing to medical bodies need comparable educational attributes to hold their own in debate with health professionals. This inevitably limits eligibility. That's life. Moreover, doctors who polled the most votes at a recent GMC by-election included one once struck off for her attitude to patients and colleagues and another fined for carrying out surgery without consent. This hardly makes the argument for election as preferable to appointment.

We can explore the feasibility of the patient movement and the voluntary sector electing non-professionals (a better expression than lay people, with its flavour of second class citizens) to the GMC. Community health councils have provided a precedent for such a system.
Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.
Authors: Gautam Borthakur, Miloslav Beran, Jun Liu, Dushyant Verma, Xiao Q Dong, Gabriela Rondon, Richard E. Champlin, Hagop Kantarjian, Uday R Popat
Journal: Blood (2008)
Peg IFNα-2a in Polycythemia Vera (PV). Results of a Phase 2 Study by the French “PV-NORD” Group.
Authors: Jean-Jacques Kiladjian, Bruno Cassinat, Pascal Turlure, Nathalie Cambier, Sylvia Bellucci, Murielle Roussel, Marie-José Grange, Bernard Grandchamp, Jean-Didier Rain, Christine Chomienne, Pierre Fenaux
Journal: Blood (2006)
Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy,
Authors: Jenny V. Pozadzides, Michael J Keating, William G. Wierda, Susan O'Brien, Jan A. Burger, Jeffrey L. Jorgensen, Steliana Calin, SA Wang, Susan Lerner, Alessandra Ferrajoli
Journal: Blood (2011)
Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,
Authors: Andrew M. Evens, Ann Vanderplas, Ann LaCasce, Allison Crosby, Auayporn Nademanee, Mark S. Kaminski, Gregory A. Abel, Michael Millenson, Myron S. Czuczman, Maria A. Rodriguez, Joyce Niland, Andrew D Zelenetz, Leo I. Gordon, Jonathan Friedberg
Journal: Blood (2011)
Oligoclonal Expansion of Revertant T Cells Leads to Omenn Syndrome in a Patient with RAG1-Deficient Severe Combined Immunodeficiency.
Authors: Taizo Wada, Hiroyuki Okamoto, Tomoko Toma, Yoshihito Kasahara, Shoichi Koizumi, Masahiko Kato, Akihiro Yachie
Journal: Blood (2004)
Mesenchymal Stem Cell Engraftment in Bone Following In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta.
Authors: Katarina Le Blanc, Cecilia Götherström, Olle Ringdén, Moustapha Hassan, Robert McMahon, Edwin Horwitz, Göran Anneren, Ove Axelsson, Janice Nunn, Uwe Ewald, Solveig Nordén-Lindeberg, Monika Jansson, Ann Dalton, Eva Åström, Magnus Westgren
Journal: Blood (2004)
Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.
Authors: Jean-Pierre J. Issa, Vazganush Gharibyan, Jaroslav Jelinek, Gail Morris, Srdan Verstovsek, Moshe Talpaz, Guillermo Garcia-Manero, Hagop M. Kantarjian
Journal: Blood (2004)
A Comparison of Clinical Outcomes of Non-T-Cell-Depleted (Non-TCD) Unrelated Donor Heamatopietic Stem Cell Transplantation (HSCT) and Non-TCD Haploidentical Related Donor HSCT.
Authors: Feng Chen, De Pei Wu, Aining Sun, Xiao Ma, Xiaowen Tang, Xiaojing Wu, Ying Wang
Journal: Blood (2006)
Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS)
Authors: Chadi Nabhan, Michelle Byrtek, Michael Taylor, Jill Tydell, Jamie H. Hirata, Christopher R Flowers
Journal: Blood (2010)
Subcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT
Authors: Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Søren Høyer, Kirsten Bouchelouche
Journal: Clinical Nuclear Medicine (2017)

We present a case of a subcutaneous process in the abdominal wall with high prostate-specific membrane antigen (PSMA) activity on 68Ga-PSMA PET/CT. Histology demonstrated a benign lobular capillary hemangioma with a high vascular density, with highly PSMA-positive endothelial cells. It is well known that PSMA is expressed in different tissue, including neovasculature in various malignant tumors, and the knowledge is rapidly evolving as new discoveries appear.
Endothelial Cell Protein C Receptor-Mediated Redistribution and Tissue-Level Accumulation of Pharmacologically Administered Recombinant Human Factor VIIa
Authors: Curtis A Clark, Rit Vatsyayan, Ramakrishnan Gopalakrishnan, Charles T Esmon, Ulla Hedner, Usha R Pendurthi, L. Vijaya Mohan Rao
Journal: Blood (2011)
Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.
Authors: G. Cimino, L. Elia, G. Meloni, L. Annino, A. Chiarenza, G. Martinelli, F. Pane, M. Montanaro, P. Chiusolo, A. Santoro, M. Offidani, M. Vignetti, G. Saglio, M. Baccarni, F. Mandelli, Robert Foa
Journal: Blood (2004)
In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.
Authors: Kerstin Jonsson-Videsater, Dina Ali, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul, Soren Lehmann
Journal: Blood (2009)
Acute Activation of Endothelium Induces Circulation of Active Von Willebrand Factor in HELLP Sydrome.
Authors: Janine J. Hulstein, Pieter J. van Runnard Heimel, Arie Franx, Peter J. Lenting, Hein W. Bruinse, Karen Silence, Philip G. de Groot, Rob Fynheer
Journal: Blood (2005)
Thalidomide Based Induction Chemotherapy Prior to Stem Cell Transplantation in Myeloma Is Associated with Decreased Response to Retreatment with Thalidomide at First Relapse Post Transplant.
Authors: Lijo Simpson, Morie Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne Hayman, Francis Buadi, Vincent S. Rajkumar, Shaji Kumar
Journal: Blood (2007)